Researchers have identified 44 genetic risk factors for major depressive disorder. 30 of the variants are newly discovered. The team reports the genetic basis for MDD is shared with other psychological disorders and all humans carry some of the genetic risk factors identified.
DNA markers in cells of patients with major depressive disorder appear to be two years older than markers in cells of people without the mental health disorder.
A new study reports aerobic exercise can have antidepressant effects for patients with major depressive disorder.
Alcohol use disorder is associated with a significant increase in suicidal thoughts in adults.
Ezogabine, an FDA approved anti-convulsant, appears to significantly reduce symptoms in those with major depressive disorder.
Antidepressants for major depressive disorder reduce the aversive response triggered by exposure to the suffering of others. Findings suggest antidepressants may lead to impaired empathy of pain perception.
Artificial intelligence technology is able to objectively differentiate between those with PTSD and those without by analyzing speech samples, with 89.1% accuracy.
Only 45% of patients with major depressive disorder find benefit from cognitive behavioral therapy (CBT). A neuroimaging study reveals those who respond to CBT have greater neural activity in the right striatum and right amygdala pretreatment than those who find little benefit from the treatment. The findings could serve as a biomarker to discover who will respond to CBT.